The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function

Eleftherios S. Xenos, Daniel Casanova, David E.R. Sutherland, Alan C. Farney, J. J. Lloveras, Paul F. Gores

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


15-deoxyspergualin (DSG) is a novel immunosuppressive agent that has been shown to prolong the function of islet allografts in both small and large animal models. The purpose of this study was to investigate the effect of DSG on in vitro glucose-induced insulin secretion by isolated islets and on glucose disposal in vivo. Incubation of human or rat islets for 24 hr in the presence of DSG (1, 2, 5 or 10 μg/ml) did not effect their secretory capacity. In addition, glucose disposal and insulin secretion by normal rats was unaffected by the daily administration of DSG (1, 4, or 10 mg/kg) for 1 week. In contrast to cyclosporine, prednisone, and FK506, DSG does not appear to be associated with altered beta cell function or disordered glucose disposal and is an attractive alternative with potential usefulness in clinical islet allotransplantation.

Original languageEnglish
Pages (from-to)144-147
Number of pages4
Issue number1
StatePublished - Jul 1993

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function'. Together they form a unique fingerprint.

Cite this